Unknown

Dataset Information

0

Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.


ABSTRACT: Chronic myeloid leukaemia (CML) is driven by the fusion protein Bcr-Abl, a constitutively active tyrosine kinase playing a crucial role in initiation and maintenance of CML phenotype. Despite the great efficacy of the Bcr-Abl-specific inhibitor imatinib, resistance to this drug is recognized as a major problem in CML treatment. We found that in LAMA84 cells, characterized by imatinib-resistance caused by BCR-ABL1 gene amplification, the pro-survival protein kinase CK2 is up-regulated as compared to the sensitive cells. CK2 exhibits a higher protein-level and a parallel enhancement of catalytic activity. Consistently, CK2-catalysed phosphorylation of Akt-Ser129 is increased. CK2 co-localizes with Bcr-Abl in the cytoplasmic fraction as judged by subcellular fractionation and fluorescence immunolocalization. CK2 and Bcr-Abl are members of the same multi-protein complex(es) in imatinib-resistant cells as demonstrated by co-immunoprecipitation and co-sedimentation in glycerol gradients. Cell treatment with CX-4945, a CK2 inhibitor currently in clinical trials, counteracts CK2/Bcr-Abl interaction and causes cell death by apoptosis. Interestingly, combination of CX-4945 with imatinib displays a synergistic effect in reducing cell viability. Consistently, knockdown of CK2α expression by siRNA restores the sensitivity of resistant LAMA84 cells to low imatinib concentrations. Remarkably, the CK2/Bcr-Abl interaction and the sensitization towards imatinib obtained by CK2-inhibition in LAMA84 is observable also in other imatinib-resistant CML cell lines. These results demonstrate that CK2 contributes to strengthen the imatinib-resistance phenotype of CML cells conferring survival advantage against imatinib. We suggest that CK2 inhibition might be a promising tool for combined strategies in CML therapy.

SUBMITTER: Borgo C 

PROVIDER: S-EPMC5528438 | BioStudies | 2013-01-01

SECONDARY ACCESSION(S): 10.1016/j.molonc.2013.08.006

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3548959 | BioStudies
1000-01-01 | S-EPMC2481545 | BioStudies
1000-01-01 | S-EPMC2893099 | BioStudies
2014-01-01 | S-EPMC3938960 | BioStudies
2016-01-01 | S-EPMC5223104 | BioStudies
2013-01-01 | S-EPMC3568121 | BioStudies
2018-01-01 | S-EPMC5859405 | BioStudies
2017-01-01 | S-EPMC5430391 | BioStudies
2020-01-01 | S-EPMC7139888 | BioStudies
2017-01-01 | S-EPMC5515395 | BioStudies